Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors. Proceeds from the sale will go to the selling shareholders.
Weak dollar trend may favor emerging markets amid US deficit concerns: Seth R Freeman
Seth R Freeman discusses the negative impact of tariffs on Mexico and Europe, highlighting the uncertainty it creates for businesses. Despite tepid market reactions, Freeman